Abstract
BackgroundTofacitinib (CP-690,550) is a novel, oral Janus kinase (JAK) inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in rheumatoid arthritis (RA). Administration of tofacitinib to patients (pts) with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have